(NASDAQ:PULM), SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE(TM) platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK […]

Registry will use HeartFlow FFRCT and Plaque Analysis to help inform strategies for prevention, earlier detection and improved care for former NFL athletes at high risk for coronary artery disease MOUNTAIN VIEW, Calif. and GREENWOOD VILLAGE, Colo., Jan. 22, 2025 (GLOBE NEWSWIRE) — HeartFlow, Inc., the global leader in non-invasive artificial intelligence (AI) heart care

(NasdaqGM:AVDL), DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient

(NYSE:TRU), NEW ORLEANS, Jan. 22, 2025 (GLOBE NEWSWIRE) — Over the coming year, many consumers considering an auto loan or lease may be reentering the market with far more complicated credit pictures than they did, even just a few years ago. The findings come from a new analysis released today by TransUnion (NYSE: TRU) in

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) — IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will leverage IMMvention's investigational small-molecule BACH1

(NASDAQ:BLBX), DALLAS, Jan. 22, 2025 (GLOBE NEWSWIRE) — Blackboxstocks Inc. (NASDAQ: BLBX), (“Blackbox” or the “Company”), a financial technology and social media hybrid platform offering real-time proprietary analytics for stock and options traders, announced today that on January 17, 2025 the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) pursuant to which the

(NasdaqGM:PUBM), NO-HEADQUARTERS/REDWOOD CITY, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) — TCL, a leading global television brand and PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising's supply chain of the future, today announced a new partnership designed to enhance programmatic advertising for live sports. This new partnership will connect TCL's premium programmatic streaming inventory,

SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Cribl, the Data Engine for IT and Security, today announced it has surpassed $200 million in annual recurring revenue (ARR), growing ARR by more than 70 percent year-over-year (YoY). This follows the company's achievement of $100 million in ARR in October 2023, when it became the fourth

(CNSX:DMED.CN),(OTC US:DGNMF),(Other OTC:DGNMF), TORONTO, Jan. 22, 2025 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading provider of innovative technology solutions for the cleantech and life sciences industries, is proud to announce a strategic collaboration with TerraVent Environmental Inc. (“TerraVent”). This partnership will advance the evaluation and integration

(AUST:RCE.AX),(Frankfurt:R9Q.F), Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327G Full data analysis expected in Q1 2025 Additional Australian regulatory trials to be initiated in H1 2025 SYDNEY, Jan. 22, 2025 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company),